Anastasia Constantinidou

Summary

Country: UK

Publications

  1. ncbi Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit
    Anastasia Constantinidou
    Melanoma Unit, Guy s and St Thomas Foundation NHS Trust, London, UK
    Melanoma Res 18:56-60. 2008
  2. ncbi Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis
    Anastasia Constantinidou
    Sarcoma Unit, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK
    Eur J Cancer 45:2930-4. 2009
  3. ncbi Informational needs of patients with melanoma and their views on the utility of investigative tests
    A Constantinidou
    Melanoma Group, Guy s and St Thomas NHS Foundation Trust, London SW156NP, UK
    Int J Clin Pract 63:1595-600. 2009
  4. ncbi Role of palliative chemotherapy in advanced epithelioid sarcoma
    Robin L Jones
    Sarcoma Unit, Royal Marsden Hospital, London, UK
    Am J Clin Oncol 35:351-7. 2012
  5. ncbi Advanced aggressive fibromatosis: Effective palliation with chemotherapy
    Anastasia Constantinidou
    Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom
    Acta Oncol 50:455-61. 2011
  6. ncbi Chemotherapy in clear cell sarcoma
    Robin L Jones
    Royal Marsden Hospital, London, UK
    Med Oncol 28:859-63. 2011
  7. ncbi Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Anastasia Constantinidou
    Breast Unit, Royal Marsden Hospital, London UK and Institute of Cancer Research, London, UK
    Breast 20:S158-61. 2011
  8. ncbi Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience
    Michael S Hofman
    PET Imaging Centre at St Thomas, Guy s and St Thomas Foundation NHS Trust, and King s College, London, UK
    Nucl Med Commun 28:902-6. 2007
  9. ncbi Beyond triple-negative breast cancer: the need to define new subtypes
    Anastasia Constantinidou
    Royal Marsden Hospital, London, UK
    Expert Rev Anticancer Ther 10:1197-213. 2010
  10. ncbi The evolution of systemic therapy in sarcoma
    Anastasia Constantinidou
    The Royal Marsden Hospital, London, UK
    Expert Rev Anticancer Ther 13:211-23. 2013

Detail Information

Publications10

  1. ncbi Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit
    Anastasia Constantinidou
    Melanoma Unit, Guy s and St Thomas Foundation NHS Trust, London, UK
    Melanoma Res 18:56-60. 2008
    ..It is questionable whether any imaging is beneficial at this stage. The results of this review suggest that PET scanning might not be indicated for this group of patients...
  2. ncbi Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis
    Anastasia Constantinidou
    Sarcoma Unit, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK
    Eur J Cancer 45:2930-4. 2009
    ..Recent reports indicate that pegylated liposomal doxorubicin (PLD) is effective...
  3. ncbi Informational needs of patients with melanoma and their views on the utility of investigative tests
    A Constantinidou
    Melanoma Group, Guy s and St Thomas NHS Foundation Trust, London SW156NP, UK
    Int J Clin Pract 63:1595-600. 2009
    ..The aim of the study was to identify the informational needs of patients with melanoma on disease status and prognosis, and to ascertain their views on the utility of positron emission tomography (PET) and sentinel node biopsy (SNB)...
  4. ncbi Role of palliative chemotherapy in advanced epithelioid sarcoma
    Robin L Jones
    Sarcoma Unit, Royal Marsden Hospital, London, UK
    Am J Clin Oncol 35:351-7. 2012
    ..The aim of this study was to investigate the response rate and progression-free survival in a series of epithelioid sarcoma patients treated with chemotherapy at a single referral center...
  5. ncbi Advanced aggressive fibromatosis: Effective palliation with chemotherapy
    Anastasia Constantinidou
    Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom
    Acta Oncol 50:455-61. 2011
    ..Aggressive fibromatosis (AF) is a locally invasive proliferative disease. The mainstay of treatment is surgery. Chemotherapy may be considered in inoperable AF following failure of hormonal therapy and/or NSAIDs...
  6. ncbi Chemotherapy in clear cell sarcoma
    Robin L Jones
    Royal Marsden Hospital, London, UK
    Med Oncol 28:859-63. 2011
    ..These data provide a reference for response and outcome in the assessment of novel agents in this histological subtype...
  7. ncbi Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Anastasia Constantinidou
    Breast Unit, Royal Marsden Hospital, London UK and Institute of Cancer Research, London, UK
    Breast 20:S158-61. 2011
    ..Meanwhile there is already enough circumstantial evidence to justify anti-HER2 therapy alone in selected patients for whom chemotherapy is contraindicated...
  8. ncbi Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience
    Michael S Hofman
    PET Imaging Centre at St Thomas, Guy s and St Thomas Foundation NHS Trust, and King s College, London, UK
    Nucl Med Commun 28:902-6. 2007
    ..This study evaluates our early experience in the use of FDG PET-CT in the assessment of early response to chemotherapy in metastatic melanoma...
  9. ncbi Beyond triple-negative breast cancer: the need to define new subtypes
    Anastasia Constantinidou
    Royal Marsden Hospital, London, UK
    Expert Rev Anticancer Ther 10:1197-213. 2010
    ..Understanding the molecular underpinning of distinct subgroups of these cancers is crucial for the identification of novel therapeutic targets and individualization of treatment for patients with triple-negative disease...
  10. ncbi The evolution of systemic therapy in sarcoma
    Anastasia Constantinidou
    The Royal Marsden Hospital, London, UK
    Expert Rev Anticancer Ther 13:211-23. 2013
    ..Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs...